FDA Will Ask Sarepta to Halt Gene Therapy Shipments
Digest more
FDA approves JUUL vapes
Digest more
A panel selected by FDA Commissioner Marty Makary, MD, MPH, unanimously urged the agency to remove the boxed warning on hormone treatments for menopause, arguing that the strong warning has likely discouraged countless women from using a treatment that may provide benefit.
The Food and Drug Administration has updated their recall of a batch of Dubai chocolate spread to Class I, their highest level, due to risk of salmonella contamination.
The U.S. Food and Drug Administration's panel of independent advisers on Friday voted against the efficacy of Otsuka Pharma's drug when used in combination with Viatris' Zoloft for the treatment of adults with PTSD.
Explore more
FRIDAY, July 18, 2025 (HealthDay News) — After years of legal battles and health concerns, Juul Labs has the go-ahead to sell some of its electronic cigarettes in the United States. The U.S. Food and Drug Administration (FDA) said that it will allow Juul to market its e-cigarette device and tobacco and menthol refill cartridges.
Rich Ice Cream Co. recalled numerous lots of its products on June 27 over potential contamination with Listeria monocytogenes.
The Food and Drug Administration is reassessing some warnings given about hormone therapy treatments for menopause that have led to some women avoiding the option, even if it could help them.
The manufacturer announced a recall of 67,214 cases of its Power Stick roll-on deodorant due to violations of Current Good Manufacturing Practices.
The 52 food standards pertain to canned fruits and vegetables, dairy products, baked goods, macaroni products, and other foods. The FDA has reviewed its portfolio of more than 250 food Standards of Identity to "make sure they are useful, relevant, and serve consumers in the best possible way."
1d
Medpage Today on MSNCRLs Are the Low-Hanging Fruit of FDA Transparency, Experts SayFor instance, "the backlog of FOIAs ... is enormous," he said. Califf said the FDA has far greater opportunities for improved transparency -- especially in the stages of the drug approval process that happen long before CRLs are issued.